China Accepts Opamtistomig NDA with Priority Review in Rare Neuroendocrine Carcinoma

Company: Nanjing Leads Biolabs · Event Type: NDA Accepted with Priority Review (China NMPA/CDE) · Asset: Opamtistomig (LBL-024) · Indication: Extrapulmonary Neuroendocrine Carcinoma · Date: August 21, 2026 Summary China’s Center for Drug Evaluation (CDE) has accepted Nanjing Leads Biolabs’ New Drug Application for opamtistomig…